Fidelity Asian Values (LON:FAS) Sets New 52-Week High at $456.00

Share on StockTwits

Fidelity Asian Values PLC (LON:FAS)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 456 ($5.96) and last traded at GBX 454 ($5.93), with a volume of 44956 shares trading hands. The stock had previously closed at GBX 454.50 ($5.94).

The business’s 50 day moving average is GBX 440.18. The stock has a market capitalization of $327.65 million and a price-to-earnings ratio of -68.79.

In related news, insider Kate Bolsover sold 2,333 shares of Fidelity Asian Values stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of GBX 425 ($5.55), for a total value of £9,915.25 ($12,956.03).

About Fidelity Asian Values (LON:FAS)

Fidelity Asian Values PLC is an investment company. Its objective is to achieve long-term capital growth principally from the stock markets of the Asian Region, excluding Japan. It seeks to meet its investment objective through investment in a diversified portfolio of securities and instruments issued by or related to companies listed on the stock markets in the Asian Region, excluding Japan, but investments may be made in companies listed elsewhere.

Recommended Story: What is the LIBOR?

Receive News & Ratings for Fidelity Asian Values Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fidelity Asian Values and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.